English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/84997
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:

DC FieldValueLanguage
dc.contributor.authorGonzález-Rey, Elena-
dc.contributor.authorDelgado, M.-
dc.date.accessioned2013-10-25T09:53:58Z-
dc.date.available2013-10-25T09:53:58Z-
dc.date.issued2007-
dc.identifierdoi: 10.1016/j.tips.2007.07.001-
dc.identifierissn: 0165-6147-
dc.identifier.citationTrends in Pharmacological Sciences 28: 482- 491 (2007)-
dc.identifier.urihttp://hdl.handle.net/10261/84997-
dc.description.abstractThe loss of immune tolerance results in the breakdown of immune homeostasis and the appearance of exacerbated inflammatory conditions. Some anti-inflammatory neuropeptides have recently emerged as endogenous factors participating in the maintenance of immune tolerance. The effects of these neuropeptides in self-tolerance primarily depend on the activation of cAMP-protein kinase A signaling and the regulation of various transduction pathways involved in the expression of many immune factors. Understanding of the structure-function relationship of anti-inflammatory neuropeptides and their receptors will facilitate the development of novel pharmacological agents for the treatment of immune disorders. © 2007 Elsevier Ltd. All rights reserved.-
dc.language.isoeng-
dc.publisherElsevier-
dc.rightsclosedAccess-
dc.titleAnti-inflammatory neuropeptide receptors: new therapeutic targets for immune disorders?-
dc.typeartículo-
dc.identifier.doi10.1016/j.tips.2007.07.001-
dc.date.updated2013-10-25T09:53:58Z-
dc.description.versionPeer Reviewed-
Appears in Collections:(IPBLN) Artículos
Files in This Item:
File Description SizeFormat 
accesoRestringido.pdf15,38 kBAdobe PDFThumbnail
View/Open
Show simple item record
 

Related articles:


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.